6 May 2021
Dr Tom Mules speaks to RNZ about how human hookworms show a remarkable ability to dampen down aggressive immune responses, offering an exciting potential for treating autoimmune or inflammatory diseases.
The Malaghan Institute's hookworm clinical therapy programme aims to explore the therapeutic benefits of the human hookworm necator americanus.
This Health Research Council funded programme involves infecting volunteers with a controlled dose of hookworm, and monitoring how they affect their hosts' health and immune profile. The study has since moved onto working with patients with ulcerative colitis, with plans to expand the programme further in the future.
Malaghan Institute clinical consultant Dr Tom Mules, a gastroenterologist in the Wellington region who is working on the hookworm programme, sat down with RNZ to discuss the wider programme and our motivations for conducting this study.
Related articles

New funding supports cutting-edge research into immune cell metabolism
13 October 2025

The Detail: The viral drift of misinformation
29 September 2025

Te Pūnaha Awhikiri: Exploring the Immune System through Mātauranga Māori
7 July 2025

Malaghan visiting researcher: Associate Professor Timothy Hand
16 June 2025

Could a forgotten vaccine help us fight both ancient diseases and modern threats?
29 May 2025

Dr Michelle Linterman: Asking the age-old question
30 April 2025